|
The Terrible Things GlaxoSmithKline Did Wrong –And The Thing It's Doing Right
Forbes Glaxo's shares are up on a down day for the Dow and for rivals such as Merck, Pfizer, and Novartis. The stock is up for three reasons: The settlement was previously disclosed by Glaxo, and came in $150 million lower than investors were expecting. Glaxo … |
View full post on world asthma day – Google News
